内皮型一酸化窒素合成酵素
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2021/10/04 19:25 UTC 版)
内皮型一酸化窒素合成酵素（ないひがたいっさんかちっそごうせいこうそ、英: endothelial nitric oxide synthase、略称: eNOS）または一酸化窒素合成酵素3（nitric oxide synthase 3、NOS3）は、ヒトでは7番染色体の7q35-7q36領域に位置するNOS3遺伝子によってコードされる酵素である[5]。この酵素は、一酸化窒素（NO）の合成を行う3つの一酸化窒素合成酵素のうちの1つである。NOは気体の親油性低分子で、いくつかの生物学的過程に関与する[6][7]。他の2つのアイソフォームは、脳の特定の神経細胞で恒常的に発現している神経型（nNOS、NOS1）[8]と、一般的には炎症性疾患で発現が誘導される誘導型（iNOS、NOS2）[9]である。eNOSは主に血管内皮でのNOの産生を担う[10]。血管内皮は血管の内側表面に並んだ単層の扁平細胞からなり、内腔を循環する血液と血管壁の残りの部分との境界面となる[11]。血管内皮でeNOSによって産生されるNOは、血管緊張、細胞増殖、白血球の接着、血小板の凝集の調節に重要な役割を果たす。そのため、健康な心臓血管系には機能的なeNOSが必要不可欠である。
- ^ a b c GRCh38: Ensembl release 89: ENSG00000164867 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028978 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Mouse PubMed Reference:
- ^ “Molecular cloning and characterization of human endothelial nitric oxide synthase”. FEBS Lett. 307 (3): 287–93. (August 1992). doi:10.1016/0014-5793(92)80697-F. PMID 1379542.
- ^ “Exploring vascular benefits of endothelium-derived nitric oxide”. American Journal of Hypertension 18 (12 Pt 2): 177S–183S. (Dec 2005). doi:10.1016/j.amjhyper.2005.09.001. PMID 16373196.
- ^ “Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease”. Free Radical Biology & Medicine 49 (3): 307–16. (Aug 2010). doi:10.1016/j.freeradbiomed.2010.04.004. PMC 2900489. PMID 20388537.
- ^ “Nitric oxide synthases: regulation and function”. European Heart Journal 33 (7): 829–37, 837a–837d. (Apr 2012). doi:10.1093/eurheartj/ehr304. PMC 3345541. PMID 21890489.
- ^ “Inducible nitric oxide synthase as a possible target in hypertension”. Current Drug Targets 15 (2): 164–74. (Feb 2014). doi:10.2174/13894501113146660227. PMID 24102471.
- ^ “Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium”. Cellular and Molecular Life Sciences 63 (2): 144–62. (Jan 2006). doi:10.1007/s00018-005-5421-8. PMID 16416260.
- ^ “Cells in focus: endothelial cell”. The International Journal of Biochemistry & Cell Biology 34 (12): 1508–12. (Dec 2002). doi:10.1016/s1357-2725(02)00075-4. PMID 12379270.
- ^ a b “Post-translational regulation of endothelial nitric oxide synthase in vascular endothelium”. Frontiers in Physiology 4: 347. (2013). doi:10.3389/fphys.2013.00347. PMC 3861784. PMID 24379783.
- ^ “Nitric oxide synthases: structure, function and inhibition”. The Biochemical Journal 357 (Pt 3): 593–615. (Aug 2001). doi:10.1042/bj3570593. PMC 1221991. PMID 11463332.
- ^ “Signal transduction of eNOS activation”. Cardiovascular Research 43 (3): 532–41. (Aug 1999). doi:10.1016/s0008-6363(99)00094-2. PMID 10690325.
- ^ “Free radical production by dysfunctional eNOS”. Heart 90 (5): 494–5. (May 2004). doi:10.1136/hrt.2003.029405. PMC 1768213. PMID 15084540.
- ^ “The regulation and pharmacology of endothelial nitric oxide synthase”. Annual Review of Pharmacology and Toxicology 46: 235–76. (2006). doi:10.1146/annurev.pharmtox.44.101802.121844. PMID 16402905.
- ^ “Subcellular localization of oxidants and redox modulation of endothelial nitric oxide synthase”. Circulation Journal 76 (11): 2497–512. (2012). doi:10.1253/circj.cj-12-1207. PMID 23075817.
- ^ “Protective role of endothelial nitric oxide synthase”. The Journal of Pathology 199 (1): 8–17. (Jan 2003). doi:10.1002/path.1250. PMID 12474221.
- ^ “Molecular mechanisms of endothelial NO synthase uncoupling”. Current Pharmaceutical Design 20 (22): 3548–53. (2014). doi:10.2174/13816128113196660746. PMID 24180388.
- ^ “Guanylate cyclase and the .NO/cGMP signaling pathway”. Biochimica et Biophysica Acta 1411 (2–3): 334–50. (May 1999). doi:10.1016/s0005-2728(99)00024-9. PMID 10320667.
- ^ “Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha”. Science 286 (5444): 1583–7. (Nov 1999). doi:10.1126/science.286.5444.1583. PMID 10567269.
- ^ “Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP”. The American Journal of Physiology 267 (5 Pt 1): C1405–13. (Nov 1994). doi:10.1152/ajpcell.1994.267.5.C1405. PMID 7977701.
- ^ “Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation”. Proceedings of the National Academy of Sciences of the United States of America 98 (7): 4202–8. (Mar 2001). doi:10.1073/pnas.071054698. PMC 31203. PMID 11259671.
- ^ “Nitric oxide in vascular biology”. Journal of Thrombosis and Haemostasis 1 (10): 2112–8. (Oct 2003). doi:10.1046/j.1538-7836.2003.00345.x. PMID 14521592.
- ^ “New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases”. Clinical Chemistry 45 (1): 7–17. (Jan 1999). PMID 9895331.
- ^ “Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training”. The Journal of Clinical Investigation 105 (11): 1631–9. (Jun 2000). doi:10.1172/JCI9551. PMC 300857. PMID 10841522.
- ^ “Ferritin: a cytoprotective antioxidant strategem of endothelium”. The Journal of Biological Chemistry 267 (25): 18148–53. (Sep 1992). PMID 1517245.
- ^ “Characterization of the human endothelial nitric-oxide synthase promoter”. The Journal of Biological Chemistry 274 (5): 3076–93. (Jan 1999). doi:10.1074/jbc.274.5.3076. PMID 9915847.
- ^ “Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression”. American Journal of Physiology. Cell Physiology 291 (5): C803–16. (Nov 2006). doi:10.1152/ajpcell.00457.2005. PMID 16738003.
- ^ “Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis”. Trends in Cell Biology 4 (7): 231–5. (Jul 1994). doi:10.1016/0962-8924(94)90114-7. PMID 14731661.
- ^ “Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity”. The Journal of Biological Chemistry 272 (30): 18522–5. (Jul 1997). doi:10.1074/jbc.272.30.18522. PMID 9228013.
- ^ “A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins”. Basic & Clinical Pharmacology & Toxicology 106 (5): 357–61. (May 2010). doi:10.1111/j.1742-7843.2010.00551.x. PMID 20210789.
- ^ “T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm”. Circulation 99 (22): 2864–70. (Jun 1999). doi:10.1161/01.cir.99.22.2864. PMID 10359729.
- ^ a b “An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension”. PLOS ONE 6 (9): e24266. (2011). doi:10.1371/journal.pone.0024266. PMC 3166328. PMID 21912683.
- ^ a b “The polymorphism for endothelial nitric oxide synthase gene, the level of nitric oxide and the risk for pre-eclampsia: a meta-analysis”. Gene 519 (1): 187–93. (Apr 2013). doi:10.1016/j.gene.2013.01.004. PMID 23375994.
- ^ “Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus”. Genetic Testing and Molecular Biomarkers 16 (6): 574–9. (Jun 2012). doi:10.1089/gtmb.2011.0218. PMID 22313046.
- ^ “The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy”. Nitric Oxide 13 (1): 88–92. (Aug 2005). doi:10.1016/j.niox.2005.04.004. PMID 15890549.
- ^ a b “Association of endothelial nitric oxide synthase gene polymorphisms (894G/T, -786T/C, G10T) and clinical findings in patients with migraine”. Neuromolecular Medicine 16 (3): 587–93. (Sep 2014). doi:10.1007/s12017-014-8311-0. PMID 24845269.
- ^ “Association of the T-786C, G894T and 4a/4b polymorphisms of the endothelial nitric oxide synthase gene with vasculogenic erectile dysfunction in Iranian subjects”. BJU International 107 (12): 1994–2001. (Jun 2011). doi:10.1111/j.1464-410X.2010.09755.x. PMID 20955262.
- ^ “Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear”. FASEB Journal 21 (11): 2655–63. (Sep 2007). doi:10.1096/fj.06-7088com. PMID 17449720.
- ^ “The association between endothelial nitric oxide synthase gene G894T polymorphism and hypertension in Han Chinese: a case-control study and an updated meta-analysis”. Annals of Human Biology 42 (2): 184–94. (Mar 2015). doi:10.3109/03014460.2014.911958. PMID 24846690.
- ^ “Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias”. Journal of Hypertension 25 (9): 1763–74. (Sep 2007). doi:10.1097/HJH.0b013e3281de740d. PMID 17762636.
- ^ “Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study”. Hypertension 44 (5): 702–7. (Nov 2004). doi:10.1161/01.HYP.0000143483.66701.ec. PMID 15364897.
- ^ a b “Association of endothelial nitric oxide synthase gene polymorphisms with type 2 diabetes mellitus: a meta-analysis”. Endocrine Journal 60 (7): 893–901. (2013). doi:10.1507/endocrj.ej12-0463. PMID 23563728.
- ^ “The association of eNOS G894T polymorphism with metabolic syndrome and erectile dysfunction”. The Journal of Sexual Medicine 9 (3): 837–43. (Mar 2012). doi:10.1111/j.1743-6109.2011.02588.x. PMID 22304542.
- ^ “eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes”. European Journal of Clinical Investigation 42 (7): 729–37. (Jul 2012). doi:10.1111/j.1365-2362.2011.02638.x. PMID 22224829.
- ^ “Effect of 27nt small RNA on endothelial nitric-oxide synthase expression”. Molecular Biology of the Cell 19 (9): 3997–4005. (Sep 2008). doi:10.1091/mbc.E07-11-1186. PMC 2526692. PMID 18614799.
- ^ “eNOS haplotype associated with hypertension in obese children and adolescents”. International Journal of Obesity 35 (3): 387–92. (Mar 2011). doi:10.1038/ijo.2010.146. PMID 20661250.
- ^ “Definition and clinical importance of haplotypes”. Annual Review of Medicine 56: 303–20. (2005). doi:10.1146/annurev.med.56.082103.104540. PMID 15660514.
- ^ “Susceptible and protective eNOS haplotypes in hypertensive black and white subjects”. Atherosclerosis 186 (2): 428–32. (Jun 2006). doi:10.1016/j.atherosclerosis.2005.08.003. PMID 16168996.
- ^ “Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus”. Atherosclerosis 189 (1): 241–6. (Nov 2006). doi:10.1016/j.atherosclerosis.2005.12.011. PMID 16427644.
- ^ “Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy”. Journal of Hypertension 24 (12): 2393–7. (Dec 2006). doi:10.1097/01.hjh.0000251899.47626.4f. PMID 17082721.
- ^ “Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy”. DNA and Cell Biology 29 (4): 171–6. (Apr 2010). doi:10.1089/dna.2009.0955. PMID 20070154.
- ^ “Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia”. Molecular Human Reproduction 16 (7): 506–10. (Jul 2010). doi:10.1093/molehr/gaq030. PMID 20457799.
- ^ “Endothelial nitric oxide synthase genotype and haplotype are not associated with diabetic retinopathy in diabetes type 2 patients”. Nitric Oxide 15 (4): 417–22. (Dec 2006). doi:10.1016/j.niox.2006.02.002. PMID 16581274.
- ^ “eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite”. Free Radical Biology & Medicine 41 (7): 1044–9. (Oct 2006). doi:10.1016/j.freeradbiomed.2006.04.026. PMID 16962929.
- ^ “Simvastatin treatment increases nitrite levels in obese women: modulation by T(-786)C polymorphism of eNOS”. Nitric Oxide 33: 83–7. (Sep 2013). doi:10.1016/j.niox.2013.07.005. PMID 23876348.
- ^ “eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril”. European Journal of Clinical Pharmacology 69 (2): 167–77. (Feb 2013). doi:10.1007/s00228-012-1326-2. PMID 22706620.
- ^ a b “Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction”. The Pharmacogenomics Journal 13 (2): 189–96. (Apr 2013). doi:10.1038/tpj.2011.49. PMID 22064666.
- ^ “Pharmacogenetics of erectile dysfunction: navigating into uncharted waters”. Pharmacogenomics 15 (11): 1519–38. (Aug 2014). doi:10.2217/pgs.14.110. PMID 25303302.
[続きの解説]
「内皮型一酸化窒素合成酵素」の続きの解説一覧
- 1 内皮型一酸化窒素合成酵素とは
- 2 内皮型一酸化窒素合成酵素の概要
- 3 構造と触媒活性
- 4 臨床的意義
- 5 関連文献
- 6 関連項目
- 内皮型一酸化窒素合成酵素のページへのリンク
